Skip to main content
Premium Trial:

Request an Annual Quote

Celera and Medco Partner on Statin Drug PGx

NEW YORK (GenomeWeb News) – Celera and Medco Health Solutions will collaborate to study whether patients who take a test for a specific gene variant are more likely to adhere to their treatment regimens for lipid-lowering statins.

Celera said today that it will work with Medco to conduct a prospective, randomized, multi-center study to find out if testing for the KIF6 variant can be a predictor for patient adherence.

The company said that current studies suggest that only 50 to 60 percent of patients who receive prescriptions for lipid-lowering drugs are still taking the medication after six months, and that only 30 to 40 percent are on the medication after two years.

Medco plans to test roughly 650 of its members for KIF6 and will compare adherence to an equally-sized control group with an unknown KIF6 status. Celera’s subsidiary Berkeley HeartLab will conduct the testing, which is set to start this fall. Medco will then monitor patient adherence over an 18-month period.

"We believe this research collaboration presents an opportunity to demonstrate an important benefit of genetic testing as we hope to show that carriers of the KIF6 variant are more likely to adhere with their physician-prescribed statin treatment," Celera’s CEO, Kathy Ordoñez, said in a statement.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.